ARTICLE | Company News
Pieris, AZ in respiratory deal for Anticalins
May 3, 2017 10:08 PM UTC
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) climbed $1.27 (53%) to $3.67 after it said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to advance up to five respiratory disease candidates developed using the biotech's Anticalin platform, including one due to enter a Phase I trial next half.
Anticalins are engineered proteins with antibody-like binding properties. According to Pieris, the therapeutics' solubility and small size relative to biologics allow them to be inhaled directly into the lungs...
BCIQ Target Profiles